Navigation Links
Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
Date:10/21/2010

MORRISTOWN, N.J., Oct. 21 /PRNewswire/ -- Actavis Inc. today announced a voluntary recall to the wholesale and retail levels only of 18 lots of Fentanyl Transdermal System 25 mcg/hour C-II patches manufactured for Actavis by Corium International in the United States.

Actavis identified one lot of 25 mcg/hour Fentanyl patch (Control/Lot # 30349) shipped to market that contained one patch that released its active ingredient faster than the approved specification in laboratory testing. An accelerated release of Fentanyl from a 25 mcg/hour patch can lead to adverse events for at-risk patients, including excessive sedation, respiratory depression, hypoventilation (slow breathing), and apnea (temporary suspension of breathing). The patches are packaged individually and boxed in quantities of five patches per box.

Fentanyl Transdermal System is indicated for the management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate release opioids.  

As a precautionary measure, although unaware of any injuries associated with this issue, in addition to the aforementioned lot, Actavis is recalling the additional Control/Lot numbers noted below due to the possibility that additional patches may release active ingredient faster than the approved specification. The Control/Lot number appears on the bottom of the product box and on the black and white side of each individual patch packaging, in the lower left corner.Recalled Control/Lot #s30041, Exp 12/201130049, Exp 12/201130066, Exp 12/201130096, Exp 01/201230097, Exp 02/201230123, Exp 01/201230241, Exp 02/201230256, Exp 02/201230257, Exp 03/201230258, Exp 03/201230349, Exp 03/201230350, Exp 03/201230391, Exp 03/201230392, Exp 04/201230429, Exp 04/201230430, Exp 04/201230431, Exp 04/201230517, Exp 04/2012Corium, a third party supplier for Actavis, manufactured the recalled patches at their Grand Rapids, Michigan facility.

Under this recall, all wholesalers and retailers are being asked to return the product they have on hand or in stock. Fentanyl patches sold by Actavis in Europe are not impacted in this recall.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Information also is available through the Actavis U.S. website at www.actavis.us by going to the "Fentanyl Recall Information" link on the front page.

Actavis has operators available to help customers, health professionals and consumers with the following information:

  • Medical Issue/Adverse Event/Product Questions: 1-877-422-7452 (24 hours/day, 7 days/week)

  • Return/Reimbursement Questions: 1-888-896-4562 (24 hours/day, 7 days/week)

  • Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

    Online:www.fda.gov/medwatch/report.htm

    Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form.

    Fax: 1-800-FDA-0178

    About Actavis Inc.Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one quarter of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Sunrise, FL and Owings Mills, MD. For more information, please visit www.actavis.us.

    About Actavis GroupActavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries, more than 10,000 employees.


    '/>"/>

    SOURCE Actavis Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Actavis Receives Approval of Alprazolam ODT in the U.S.
    2. Actavis Launches Generic Version of Flomax(R) In The U.S.
    3. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
    4. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
    5. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
    6. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
    7. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
    8. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
    9. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    10. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
    11. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die Guian ... Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden Strategien ... einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
    (Date:2/23/2017)... New York , February 23, 2017 ... implications arising from increasing caseload for varicose veins in ... across the globe are prompting the adoption of endovenous ... study on global endovenous laser therapy market, ... towards aftereffects of lifestyle choices and consequences of obesity ...
    (Date:2/23/2017)... -- As National Nutrition Month approaches, USA Medical is providing ... people live healthier lives by providing discounts on ... all 50 states including:  Texas Prescription Assistance Program ... Assistance Program . USA Medical also shares ... nutritious eating habits: Limit ...
    Breaking Medicine Technology:
    (Date:2/23/2017)... ... , ... The 89th Academy Awards will be celebrated this weekend, which means ... Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the ... Center for American Progress (CAP), for its report, Lessons From State Performance on NAEP: ...
    (Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
    (Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
    (Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at 10075 ... Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... who have earned high ratings and superior patient reviews from multiple credible sources. , ...
    (Date:2/23/2017)... ... , ... Current Meditation , a new meditation concept ... U.S. starting this spring. Current Meditation focuses on “meditation for the modern world,” ... will be the first meditation concept in the U.S. offering franchising opportunities, setting ...
    Breaking Medicine News(10 mins):